Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Financial Statements
Historical financial data — 41 statements covering FY2024–FY2025
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high u...
Madrigal Pharmaceuticals, Inc. Common Stock's revenue increased 82.1% year over year, from $350.1M to $637.3M.
Net income decreased 98.9% over the same period, from $-115.5M to $-229.7M.
Over the 1-year period from FY2024 to FY2025, revenue grew by 4254% in total.
Total debt increased by 187.0% to $339.8M.
The debt-to-equity ratio stands at 0.54, indicating a moderate leverage profile.
Operating cash flow grew 58.7% to $-56.1M.
Madrigal Pharmaceuticals, Inc. Common Stock maintains a negative net profit margin of -36.0%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2024 | $14.6M | $-299.5M | N/A | $-314.6M | $-284.1M | $1.10B | $116.6M | $857.1M |
| Q3 FY2024 | $62.2M+324.8% | $-107.0M | N/A | $-116.3M | $-67.0M | $1.07B | $117.1M | $777.2M |
| Q1 FY2025 | $137.3M+120.7% | $-73.2M | N/A | $-79.3M | $-88.9M | $996.6M | $118.0M | $710.6M |
| Q2 FY2025 | $212.8M+55.0% | $-42.3M | N/A | $-47.2M | $-47.1M | $1.02B | $118.4M | $696.0M |
| Q3 FY2025 | $287.3M+35.0% | $-114.2M | N/A | $-114.0M | $79.8M | $1.36B | $339.8M | $625.7M |
Balance Sheet Summary (Latest Period)
Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Financial Statements & Revenue History
Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry trading at $513.21 with a market capitalization of $12. This page provides 41 historical financial statements for Madrigal Pharmaceuticals, Inc. Common Stock, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Madrigal Pharmaceuticals, Inc. Common Stock reported revenue of $637 million, representing 82.1% year-over-year growth. The net profit margin of -36.0% indicates the company is currently unprofitable. The debt-to-equity ratio of 0.54 reflects moderate leverage.
MDGL Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Madrigal Pharmaceuticals, Inc. Common Stock's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether MDGL is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track MDGL's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Madrigal Pharmaceuticals, Inc. Common Stock converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of MDGL's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use MDGL Financial Data
Investors use Madrigal Pharmaceuticals, Inc. Common Stock's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare MDGL's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how MDGL's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View MDGL's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Madrigal Pharmaceuticals, Inc. Common Stock's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.MDGL trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.